Comerica Bank
NTLA icon

Comerica Bank’s Intellia Therapeutics NTLA Stock Holding History

Comerica Bank’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$25.8K Buy
2,869
+901
+46% +$12.4K ﹤0.01% 3038
2025
Q3 		$34K Buy
1,968
+752
+62% +$9.26K ﹤0.01% 2945
2025
Q2 		$11.4K Buy
1,216
+52
+4% +$427 ﹤0.01% 3181
2025
Q1 		$8.28K Sell
1,164
-33,805
-97% -$341K ﹤0.01% 3215
2024
Q4 		$408K Sell
34,969
-611
-2% -$9.54K ﹤0.01% 1975
2024
Q3 		$731K Sell
35,580
-352
-1% -$8.12K ﹤0.01% 1712
2024
Q2 		$804K Sell
35,932
-1,173
-3% -$27.9K ﹤0.01% 1607
2024
Q1 		$1.02M Buy
37,105
+33,214
+854% +$923K ﹤0.01% 1527
2023
Q4 		$119K Sell
3,891
-6,694
-63% -$192K ﹤0.01% 2441
2023
Q3 		$335K Buy
+10,585
New +$411K ﹤0.01% 1983
2021
Q3 		– Sell
-1,770
Closed -$255K – 2306
2021
Q2 		$255K Buy
+1,770
New +$138K ﹤0.01% 2190

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Comerica Bank's NTLA Position: Q4 2025 in Review

Comerica Bank increased its Intellia Therapeutics (NTLA) stake by 46% in Q4 2025, buying an estimated $12.4K and bringing the position to 2,869 shares worth $25.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3038.

Comerica Bank first reported a position in NTLA in Q2 2021 and has held it in 11 quarters since. The position peaked at $1.02M in Q1 2024. 292 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.

  • Comerica Bank held 2,869 shares of Intellia Therapeutics worth $25.8K as of Q4 2025.
  • Comerica Bank bought 901 Intellia Therapeutics shares in Q4 2025, an estimated $12.4K.
  • Intellia Therapeutics made up ﹤0.01% of Comerica Bank's portfolio in Q4 2025, its #3038 holding.
  • Comerica Bank first reported a position in Intellia Therapeutics in Q2 2021 and has held it in 11 quarters since.
  • Comerica Bank's Intellia Therapeutics position peaked at $1.02M in Q1 2024.
  • 292 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.

Based on Comerica Bank's 13F filing for Q4 2025, filed 29 Jan 2026.